Novo Nordisk, the global leader in insulin production, has announced the acquisition of Biocorp, a French medtech company specialized in connected drug delivery devices. The transaction began with the acquisition of the 45.3% stake held by the main shareholder, Bio Jag, followed by a mandatory simplified tender offer for the remaining shares.

The transaction values BIOCORP at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.